The primary objectives of this trial are to:

• Characterize the safety and tolerability of TEV-56278
• Determine the Recommended Phase 2 Dose (RP2D)
• Evaluate antitumor activity of TEV-56278 (Part 2 only)
• Determine the safety and tolerability of TEV-56278 in combination with pembrolizumab
• Determine a RP2D of TEV-56278 in combination with pembrolizumab

The secondary objectives of this trial are to:

• Characterize the serum pharmacokinetics of TEV-56278
• Evaluate the antitumor activity of TEV-56278
• Determine the safety and tolerability of TEV-56278
• Evaluate other measures of antitumor activity of TEV-56278
• Evaluate anti-tumor activity

Participants will be treated up to 12 months with a follow-up period of up to 12 months after last infusion. The total duration of the trial will be up to 25 months for individual participants.

Participants who exhibit a favorable benefit risk profile at the end of the 12 month trial treatment period may be offered an opportunity for an extended treatment period in which they can be treated for a maximum of 12 additional months (up to 26 additional cycles of TEV-56278).

Inclusion Criteria:

• Have an established histological diagnosis of selected solid tumor and must have received and progressed on established standard therapies or have been intolerant to such therapy or have been considered by the Investigator as ineligible for approved standard therapy
• Have a life expectancy≥12 weeks at the time of the screening
• Women of childbearing potential must agree to use highly effective methods of contraception for the course of the trial through 120 days after the last dose of trial medication
• Males who are sexually active with women of childbearing potential must agree to use condoms and refrain from donating sperm for the course of the trial through 120 days after the last dose of trial medication

NOTE- Additional criteria apply, please contact the investigator for more information

Exclusion Criteria:

• Has a history of systemic treatment therapy for cancer (including chemotherapy, immunotherapy, radiotherapy, or other investigational drug) or surgery within 4 weeks prior to baseline
• Is currently receiving or has received hematopoietic colony-stimulating growth factors within 2 weeks before screening or transfusion support 4 weeks prior to screening
• Has a diagnosis of immunodeficiency
• Has active known autoimmune disease.
• Has a history of or known active brain metastases and/or carcinomatous meningitis and/or leptomeningeal metastasis
• Has active or uncontrolled serious infections requiring systemic therapy within 14 days prior to baseline
• Has a history of clinically significant cardiovascular or cerebrovascular disease in previous 6 months prior to screening
• Has evidence of clinically significant interstitial lung disease or active, noninfectious pneumonitis
• Has a seizure disorder requiring therapy (such as steroids or antiepileptics)

NOTE- Additional criteria apply, please contact the investigator for more information

Qualified researchers may request access to patient level data and related study documents including the study protocol and the statistical analysis plan. Requests will be assessed for scientific merit, product approval status, and conflicts of interest. If the request is approved, patient level data will be de-identified and study documents will be redacted to protect the privacy of trial participants and to protect commercially confidential information. Please email USMedInfo@tevapharm.com to make your request.